TELA Bio, Inc. (NASDAQ:TELA) Major Shareholder Sells $64,116.00 in Stock

TELA Bio, Inc. (NASDAQ:TELA) major shareholder Orbimed Advisors Llc sold 13,700 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $4.68, for a total value of $64,116.00. Following the transaction, the insider now owns 2,443,842 shares in the company, valued at approximately $11,437,180.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

• On Friday, June 28th, Orbimed Advisors Llc sold 378,000 shares of TELA Bio stock. The shares were sold at an average price of $4.74, for a total value of $1,791,720.00.

TELA Bio Trading Down 5.6 %

Shares of TELA opened at $4.35 on Friday. TELA Bio, Inc. has a 12-month low of $4.23 and a 12-month high of $10.84. The firm has a 50-day moving average price of $5.34 and a 200 day moving average price of $5.92. The company has a debt-to-equity ratio of 2.83, a current ratio of 4.13 and a quick ratio of 3.23.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. The firm had revenue of $16.60 million for the quarter, compared to analysts’ expectations of $15.90 million. TELA Bio had a negative return on equity of 155.26% and a negative net margin of 63.82%. During the same period in the prior year, the firm posted ($0.63) earnings per share. On average, sell-side analysts expect that TELA Bio, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Trading of TELA Bio

A number of hedge funds and other institutional investors have recently modified their holdings of TELA. Sectoral Asset Management Inc. lifted its position in TELA Bio by 194.3% in the third quarter. Sectoral Asset Management Inc. now owns 525,000 shares of the company’s stock valued at $4,200,000 after buying an additional 346,628 shares during the last quarter. First Light Asset Management LLC lifted its holdings in shares of TELA Bio by 7.8% in the 1st quarter. First Light Asset Management LLC now owns 2,754,028 shares of the company’s stock worth $15,615,000 after acquiring an additional 199,387 shares during the last quarter. HighMark Wealth Management LLC purchased a new position in shares of TELA Bio during the 1st quarter worth approximately $1,099,000. AIGH Capital Management LLC increased its holdings in TELA Bio by 10.0% in the 4th quarter. AIGH Capital Management LLC now owns 1,377,945 shares of the company’s stock valued at $9,122,000 after purchasing an additional 125,000 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in TELA Bio by 107.6% in the first quarter. Russell Investments Group Ltd. now owns 94,940 shares of the company’s stock valued at $538,000 after purchasing an additional 49,204 shares during the period. 94.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TELA has been the subject of a number of research analyst reports. Piper Sandler restated an “overweight” rating and set a $10.00 price objective (down from $12.00) on shares of TELA Bio in a research report on Friday, May 10th. JMP Securities restated a “market outperform” rating and set a $15.00 price target on shares of TELA Bio in a research report on Friday, March 22nd.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.